477 related articles for article (PubMed ID: 17049216)
1. [Successful treatment with caspofungin of an invasive candidosis resistant to liposomal amphotericin B in a neutropenic patient].
Rome A; André N; Michel A; Coze C; Gentet JC; Bernard JL
Arch Pediatr; 2006 Dec; 13(12):1556-7. PubMed ID: 17049216
[No Abstract] [Full Text] [Related]
2. Voriconazole for candidosis: an important addition?
Graybill JR
Lancet; 2005 Oct 22-28; 366(9495):1413-4. PubMed ID: 16243074
[No Abstract] [Full Text] [Related]
3. Caspofungin in combination with amphotericin B against Candida glabrata.
Barchiesi F; Spreghini E; Fothergill AW; Arzeni D; Greganti G; Giannini D; Rinaldi MG; Scalise G
Antimicrob Agents Chemother; 2005 Jun; 49(6):2546-9. PubMed ID: 15917570
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of liposomal amphotericin B refractory Candida glabrata fungaemia in a patient undergoing a stem cell transplantation.
Veldman BA; Verweij PE; Blijlevens NM
Neth J Med; 2006 Apr; 64(4):127-9. PubMed ID: 16609161
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment with caspofungin of hepatosplenic candidiasis resistant to liposomal amphotericin B.
Sorà F; Chiusolo P; Piccirillo N; Pagano L; Laurenti L; Farina G; Sica S; Leone G
Clin Infect Dis; 2002 Nov; 35(9):1135-6. PubMed ID: 12384850
[No Abstract] [Full Text] [Related]
7. Invasive candidiasis in cancer patients: observations from a randomized clinical trial.
DiNubile MJ; Hille D; Sable CA; Kartsonis NA
J Infect; 2005 Jun; 50(5):443-9. PubMed ID: 15907554
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of Candida krusei fungemia with amphotericin B and caspofungin.
Olver WJ; Scott F; Shankland GS
Med Mycol; 2006 Nov; 44(7):655-7. PubMed ID: 17071561
[TBL] [Abstract][Full Text] [Related]
9. Comparison of caspofungin and amphotericin B for invasive candidiasis.
Mora-Duarte J; Betts R; Rotstein C; Colombo AL; Thompson-Moya L; Smietana J; Lupinacci R; Sable C; Kartsonis N; Perfect J;
N Engl J Med; 2002 Dec; 347(25):2020-9. PubMed ID: 12490683
[TBL] [Abstract][Full Text] [Related]
10. The efficiency of the benzothiazole APB, the echinocandin micafungin, and amphotericin B in fluconazole-resistant Candida albicans and Candida dubliniensis.
Melkusová S; Bujdáková H; Volleková A; Myoken Y; Mikami Y
Pharmazie; 2004 Jul; 59(7):573-4. PubMed ID: 15296100
[TBL] [Abstract][Full Text] [Related]
11. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient.
Krogh-Madsen M; Arendrup MC; Heslet L; Knudsen JD
Clin Infect Dis; 2006 Apr; 42(7):938-44. PubMed ID: 16511756
[TBL] [Abstract][Full Text] [Related]
12. Caspofungin therapy of neonates with invasive candidiasis.
Odio CM; Araya R; Pinto LE; Castro CE; Vasquez S; Alfaro B; Sàenz A; Herrera ML; Walsh TJ
Pediatr Infect Dis J; 2004 Dec; 23(12):1093-7. PubMed ID: 15626944
[TBL] [Abstract][Full Text] [Related]
13. Development of candidemia on caspofungin therapy: a case report.
Cheung C; Guo Y; Gialanella P; Feldmesser M
Infection; 2006 Dec; 34(6):345-8. PubMed ID: 17180591
[TBL] [Abstract][Full Text] [Related]
14. Acquired resistance to echinocandins in Candida albicans: case report and review.
Baixench MT; Aoun N; Desnos-Ollivier M; Garcia-Hermoso D; Bretagne S; Ramires S; Piketty C; Dannaoui E
J Antimicrob Chemother; 2007 Jun; 59(6):1076-83. PubMed ID: 17468115
[TBL] [Abstract][Full Text] [Related]
15. Caspofungin: a major breakthrough in treatment of systemic fungal infections.
Agarwal MB; Rathi SA; Ratho N; Subramanian R
J Assoc Physicians India; 2006 Dec; 54():943-8. PubMed ID: 17334012
[TBL] [Abstract][Full Text] [Related]
16. Topical caspofungin for treatment of keratitis caused by Candida albicans in a rabbit model.
Goldblum D; Frueh BE; Sarra GM; Katsoulis K; Zimmerli S
Antimicrob Agents Chemother; 2005 Apr; 49(4):1359-63. PubMed ID: 15793112
[TBL] [Abstract][Full Text] [Related]
17. Antifungal resistance: the clinical front.
Perfect JR
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 13):15-22. PubMed ID: 15682590
[TBL] [Abstract][Full Text] [Related]
18. Sequential therapy with caspofungin and fluconazole for Candida albicans infection.
Barchiesi F; Spreghini E; Baldassarri I; Marigliano A; Arzeni D; Giannini D; Scalise G
Antimicrob Agents Chemother; 2004 Oct; 48(10):4056-8. PubMed ID: 15388480
[TBL] [Abstract][Full Text] [Related]
19. Activities of flucytosine, fluconazole, amphotericin B, and micafungin in a murine model of disseminated infection by Candida glabrata.
Mariné M; Serena C; Fernández-Torres B; Pastor FJ; Guarro J
Antimicrob Agents Chemother; 2005 Nov; 49(11):4757-9. PubMed ID: 16251323
[TBL] [Abstract][Full Text] [Related]
20. Severe Candida albicans panophthalmitis treated with all available and potentially effective antifungal drugs: fluconazole, liposomal amphotericin B, caspofungin, and voriconazole.
Manfredi R; Sabbatani S
Scand J Infect Dis; 2006; 38(10):950-1. PubMed ID: 17008248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
